Why Your CJC+Ipamorelin Isn't Working on Retatrutide

Your pituitary releases growth hormone in pulses, and those pulses are controlled by two competing signals. Something called GHRH, which is the hormone that tells your pituitary to fire, and something called somatostatin, which is the hormone that tells your pituitary to stop. Growth hormone secretagogues like CJC-1295 and Ipamorelin work by amplifying the GHRH signal and suppressing somatostatin at the same time, which produces a much larger pulse than your body would generate on its own.

But there is a third variable that most people running these peptides do not account for, and that is insulin.

When insulin is elevated, it binds to receptors on the somatotroph cells in your pituitary, which are the cells responsible for producing and releasing growth hormone, and it suppresses the pulse. This is why every protocol for growth hormone secretagogues includes the instruction to inject fasted. The logic is straightforward: eating raises insulin, insulin blunts the GH pulse, so you wait until insulin comes back down before you inject. The standard recommendation has always been two hours after your last meal.

That rule was built around normal digestion.

When you eat a meal, your stomach breaks it down and moves it into the small intestine, where nutrients get absorbed and trigger insulin release. The rate at which this happens is called gastric emptying, and under normal circumstances, it follows a fairly predictable curve. About half of a solid meal leaves your stomach within roughly two hours, which is where the two-hour fasting rule comes from.

GLP-1 receptor agonists change that curve significantly.

GLP-1, which stands for glucagon-like peptide-1, is a hormone your gut naturally releases after eating, and one of its jobs is to slow down gastric emptying so that nutrients enter your bloodstream at a more controlled rate. Drugs like semaglutide and the GLP-1 component of retatrutide amplify this signal far beyond what your body would produce naturally, which means food sits in your stomach considerably longer than it would otherwise.

Researchers measured exactly how much longer. In a study using semaglutide, gastric half-emptying time increased from 118 minutes to 171 minutes. That is roughly 45 additional minutes just to reach the halfway point. At the two-hour mark specifically, there was 25.5 percent more food still retained in the stomach compared to people not on the drug. At three hours, that gap had widened to 38 percent more retained.

So the situation actually gets worse, not better, as time passes.

This has real consequences for anesthesiology. The clinical concern with full stomachs before surgery is aspiration, and the standard pre-operative fasting window was built on the assumption of normal gastric emptying. The data on GLP-1 drugs became significant enough that anesthesiologists updated their guidelines because they could no longer assume a patient's stomach was empty after the standard fasting period. A separate analysis found that patients on GLP-1 receptor agonists had gastric half-emptying of 138 minutes compared to 95 minutes in the control group, and some patients still had retained solid gastric contents after fasting for seven to eighteen hours.

Seven to eighteen hours.

Now apply that to your evening injection window. You eat dinner at seven. You wait the standard two hours and inject your CJC and Ipamorelin at nine. Under normal digestion, that window would be close to adequate. On a GLP-1 drug, you still have roughly a quarter of that meal sitting in your stomach, your small intestine is still absorbing nutrients, and your insulin is still meaningfully elevated. The somatotroph cells in your pituitary are still receiving that suppressive signal.

You inject anyway. The GHRH analog and the ghrelin mimetic both reach your pituitary and try to trigger a pulse, but they are working against active insulin suppression. You are running a compound specifically designed to amplify your growth hormone output while simultaneously running a drug that is keeping the brake pressed. The pulse either does not happen or happens at a fraction of its potential amplitude.

This applies to every secretagogue that requires fasted dosing. Tesamorelin, Sermorelin, Ipamorelin alone, GHRP-6, any compound whose mechanism depends on a low-insulin environment will be compromised by this same interaction.

The fix is straightforward once you understand the problem.

The overnight fast is the one window that GLP-1-mediated gastric slowing cannot meaningfully disrupt, because eight to ten hours of fasting is long enough that even significantly delayed digestion has run its course. Morning injection, before your first meal, gives you a baseline insulin environment that is as close to ideal as you are going to get while on these drugs. The 1990 data from Jorgensen and colleagues showed that 24-hour IGF-1 levels were equivalent between morning and evening injection timing in GH-deficient patients, so you are not sacrificing anything by moving the window.

After you inject, wait 30 to 60 minutes before eating your first meal. This is not just about avoiding insulin suppression of the pulse. Your liver needs insulin present to convert circulating growth hormone into IGF-1, which is the downstream hormone responsible for most of the tissue-building effects people are actually after. The growth hormone pulse happens in that 30 to 60 minute window, and then eating triggers the insulin response that drives IGF-1 conversion.

The timing is not arbitrary. It is the sequence that matches the biology.

What this situation illustrates is something that matters beyond this specific stack. Every compound you add to a protocol changes the environment that your other compounds are operating in. Retatrutide was not designed to interfere with growth hormone peptides, and the people who originally wrote the two-hour fasting rule were not thinking about GLP-1 induced gastric slowing. Neither piece of information was wrong on its own. They just were not written with each other in mind, and when you combine them without accounting for the interaction, the mechanism that makes your peptides work stops functioning the way you expect.

The standard rules were built for standard physiology. When you change the physiology, you have to update the rules.

---

References

1. Urva S, Coskun T, Loghin C, et al. 2023. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes, Obesity and Metabolism. Finding: Retatrutide at doses ≥3mg delayed acetaminophen Tmax by approximately 1 hour, with effects persisting at Day 30 and Day 79. Source
2. Jensterle M, et al. 2023. Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes, Obesity and Metabolism. Finding: Gastric half-emptying time increased from 118 minutes to 171 minutes on semaglutide. At 2 hours, 25.5% more gastric contents retained vs placebo. At 3 hours, 38% more retained. Source
3. Silveira SQ, et al. 2023. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. Journal of Clinical Endocrinology \& Metabolism. Finding: GLP-1 RA patients had gastric half-emptying of 138 minutes vs 95 minutes on placebo. Patients fasting 7-18 hours still had retained solid gastric contents. Source
4. Jorgensen JO, et al. 1990. Evening versus morning injections of growth hormone in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites. J Clin Endocrinol Metab. Finding: 24-hour IGF-1 levels were equivalent between morning and evening injection timing. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness